Valuation: Polaryx Therapeutics, Inc.

Market Cap 107M 93.65M 88.02M 80.33M 151M 10.25B 151M 1.06B 408M 5.23B 402M 394M 16.87B P/E 2026 *
-11x
P/E 2027 * -7.48x
Enterprise Value 107M 93.65M 88.02M 80.33M 151M 10.25B 151M 1.06B 408M 5.23B 402M 394M 16.87B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
30.08%
Yield 2026 *
-
Yield 2027 * -
1 day+0.47%
1 week+5.13%
Current month+6.97%
1 month+3.86%
3 months-10.79%
6 months-61.19%
1 week 2.02
Extreme 2.02
2.2
1 month 1.85
Extreme 1.85
2.2
Current year 1.85
Extreme 1.85
48.91
1 year 1.85
Extreme 1.85
48.91
3 years 1.85
Extreme 1.85
48.91
5 years 1.85
Extreme 1.85
48.91
10 years 1.85
Extreme 1.85
48.91
Manager TitleAgeSince
Chief Executive Officer 56 2023-02-28
Director of Finance/CFO 60 2024-05-31
Chief Tech/Sci/R&D Officer 56 2026-08-31
Director TitleAgeSince
Chairman 56 2021-05-31
Director/Board Member 60 2025-07-31
Director/Board Member - 2026-01-28
Date Insider Type Main position Quantity % Market Cap. Importance
5/27/26 Buy

Chief Executive Officer

88,453 0.1868%
2/18/26 Buy

Chief Financial Officer

2,867 -
1/29/26 Other

Chief Financial Officer

225,358 -
Change 5-day change 1-year change 3-year change Capi.($)
+0.47%+5.13% - - 107M
+2.55%+4.77%+4.07%+32.02% 47.86B
+0.08%+0.16%+43.79%+35.89% 44.46B
+0.66%+6.23%+8.96%+93.14% 41.85B
+0.05%-5.86%+334.27%+542.87% 41.34B
-1.60%+0.56%+10.84%+46.93% 30.04B
+0.96%+1.56%+26.52%+159.67% 17.59B
-0.01%-0.92% - - 15.6B
+1.15%+7.46%+25.97%+43.93% 15.69B
-1.08%+12.11%-10.11% - 13.93B
Average +0.35%+3.14%+55.54%+136.35% 26.85B
Weighted average by Cap. +0.49%+2.14%+68.82%+143.93%

Financials

2026 *2027 *
Net sales - -
Net income -9.16M -8.01M -7.53M -6.87M -12.89M -876M -12.89M -90.34M -34.86M -447M -34.41M -33.66M -1.44B -16.42M -14.35M -13.49M -12.31M -23.11M -1.57B -23.11M -162M -62.48M -802M -61.68M -60.33M -2.59B
Net Debt - -
Logo Polaryx Therapeutics, Inc.
Polaryx Therapeutics, Inc. is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (LSDs). Its drug candidate pipeline includes PLX-200 (gemfibrozil), PLX-300 (cinnamic acid), PLX-100, and PLX-400. PLX-200 (gemfibrozil), its advanced drug candidate, is an oral small molecule for the treatment of LSDs. PLX-200 is a repurposed drug that the Company is pursuing through a 505(b)(2) regulatory pathway and is designed to be administered through a novel and proprietary oral solution. PLX-300 (cinnamic acid) is a novel, oral small molecule therapy in IND-enabling studies for the treatment of LSDs. PLX-300 is an unsaturated carboxylic acid that occurs naturally in several plants as a deaminated product of phenylalanine. PLX-100 is a preclinical stage orally administrable combination therapy comprised of its PPARa agonist, PLX-200, and vitamin A, a RXRa agonist.
Employees
-
Date Price Change Volume
26-09-22 US$2.150 +0.47% 25,190
26-09-21 US$2.140 +4.90% 32,086
26-09-18 US$2.040 -4.67% 81,507
26-09-17 US$2.140 +5.42% 27,550
26-09-16 US$2.030 -0.73% 28,030
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.150USD
Average target price
7.500USD
Spread / Average Target
+248.84%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PLYX Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!